Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 30, 2026, details the results of Pharmacyte Biotech, Inc.'s annual meeting of stockholders held on that date. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC under the symbol PMCB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders representing approximately 55.08% of outstanding voting shares participated in the meeting. Five proposals were voted upon:
- Proposal 1 (Election of Directors): All five nominees (Joshua N. Silverman, Jonathan L. Schechter, Michael M. Abecassis, Robert Weinstein, and Wayne R. Walker) were elected.
- Proposal 2 (Ratification of Auditors): Stockholders approved the selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending April 30, 2026.
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation was approved.
- Proposal 4 (Reverse Stock Split): Stockholders approved an amendment to the Articles of Incorporation granting the Board authority to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100.
- Proposal 5 (Equity Plan Amendment): Stockholders approved an amendment to the 2022 Equity Incentive Plan to increase the number of shares available for grant by 2,000,000 shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. The approval of the reverse stock split authority indicates a potential strategic move to adjust the share structure, though the Board is not required to execute it immediately.
Key Facts for Investor Verification
- Verify the specific terms and timing of the potential reverse stock split, as the Board now has discretion to act within a 1-for-1.1 to 1-for-100 range.
- Review the full text of the amended 2022 Equity Incentive Plan (Exhibit 10.1) to understand the impact of the 2,000,000 share increase on dilution.
- Confirm the fiscal year-end date of April 30, 2026, when reviewing upcoming financial reports.
- Note that the company is not an emerging growth company as defined by the Securities Act.